Aa+ Aa Aa-

Prof. Dr. Tim Friede

Kurzbiographie

Seit Januar 2010 ist Tim Friede Professor für Biostatistik an der Universitätsmedizin Göttingen. Nach seinem Diplom in Mathematik an der Universität Karlsruhe (TH) wurde er an der Medizinischen Fakultät der Universität Heidelberg zum Dr.sc.hum promoviert. Im Januar 2001 ging er nach Lancaster ans Department of Mathematics and Statistics zunächst als NHS Training Fellow in Medical Statistics und später als Lecturer in Biostatistics. Von 2004 arbeitete er bei der Novartis Pharma AG in Basel, bevor er im Herbst 2006 an die Warwick Medical School als Associate Professor of Medical Statistics ging.

Seine Forschungsinteressen sind vorallem auf dem Gebiet der Designs für klinische Studien mit einem Schwerpunkt auf adaptive Designs und speziell Fallzahlrekalkulation. Seit 2009 ist Tim Friede Editor-in-Chief des Biometrical Journals (www.biometrical-journal.com) zusammen mit Prof. Dr. Leonhard Held (Zürich).
Ausgewählte Publikationen

In Druck
• Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, Obed A (2012) Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. American Journal of Transplantation (in press).
• Gross O, Friede T, Hilgers R, Görlitz A, Gavenis K, Ahmed R, Dürr U (2011) Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients. ISRN Pediatrics (in press).
• Friede T, Miller F (2011) Blinded continuous monitoring of nuisance parameters in clinical trials. Journal of the Royal Statistical Society Series C (in press).
• Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T (2011) Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis Journal (in press).
• Gerlinger C, Edler L, Friede T, Kieser M, Nakas CT, Schumacher M, Seldrup J, Victor N (2011) Considerations on what constitutes a ”Qualified Statistician” in regulatory guidelines. Statistics in Medicine (in press).

2012
• Seegers J, Vos MA, Willems R, Flevari P, Dorenkamp M, Sohns C, Vollmann D, Lüthje L, Kremastinos DT, Floré V, Meine M, Tuinenburg A, Connelly DT, Myles RC, Marshall GE, Simon D, Brockmöller J, Friede T, Hasenfuß G, Lehnart SE, Zabel M for the EUTrigTreat Clinical Study Investigators (2012) Rationale, objectives and design of the EUTrigTreat Clinical Study: A prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarisation markers and genotype. EP-Europace 14: 416–422.
• Parsons N, Friede T, Todd S, Valdés-Márquez E, Chataway J, Nicholas R, Stallard N (2012) An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56: 1150-1160.

2011
• Gross O , Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JHH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P, and Study Group Members of the Gesellschaft für Pädiatrische Nephrologie (GPN), Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Torra R, Friede T, Lange K, Müller GA, Weber M. (2011). Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International 81: 494–501.
• Thapar A, Lane T, Nicholas R, Friede T, Ellis M, Assenheim J, Franklin IJ, Davies AH (2011) Systematic review of sonographic CCSVI findings in multiple sclerosis. Phlebology 26: 319-25. [Abstract].
• Nicholas R, Straube S, Schmidli H, Schneider S, Friede T (2011) Trends in annualized relapse rates in relapsing remitting multiple sclerosis and consequences for clinical trial design. Multiple Sclerosis Journal 2011; 17: 1211-1217. [Abstract]
• Jung K, Friede T, Beißbarth T (2011) Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes. BMC Bioinformatics 12:288. [PDF]
• Clarke A, Friede T, Putz R, Ashdown J, Martin S, Blake A, Adi Y, Parkinson J, Flynn P, Platt S, Stewart-Brown S. (2011) Warwick-Edinburgh Mental Well-being Scale (WEMWBS): Validated for teenage school students in England and Scotland. A mixed methods assessment. BMC Public Health 11: 487. [PDF]
• Friede T, Parsons N, Stallard N, Todd S, Valdés-Márquez E, Chataway J, Nicholas R (2011) Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine 30: 1528-1540. [Abstract]
• Friede T, Kieser M (2011) Reassessment of sample size in internal pilot study designs for non-inferiority trials evaluated with ANCOVA. Methods of Information in Medicine 50: 237-243. [Abstract].
• Nicholas R, Giannetti P, Alanousi A, Friede T, Muraro PA (2011) Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Design, Development and Therapy 5: 255–274. [PDF].
• Hua TD, Vormfelde SV, Abu Abed M, Schneider-Rudt H, Sobotta P, Friede T, Chenot JF (2011) Practice nursed-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a cluster-randomized controlled trial. BMC Family Practice 12: 17. [abstract]
• Patel S, Brown S, Friede T, Griffiths F, Lord J, Thistlethwaite J, Tysall C, Woolvine M, Underwood M (2011) Study protocol: Improving patient choice in treating low back pain (IMPACT - LBP): A randomised controlled trial of a decision support package for use in physical therapy. BMC Musculoskeletal Disorders 12: 52. [PDF]
• Friede T, Kieser M (2011) Blinded sample size recalculation for clinical trials with Normal data and baseline adjusted analysis. Pharmaceutical Statistics 10: 8 - 13.
• Kieser M, Friede T (2011) Authors’ reply to Comments by G. Li on ‘Planning and analysis of three-arm non-inferiority trials with binary endpoints’. Statistics in Medicine 30: 300.
• Chataway J, Nicholas R, Todd, S, Parsons N, Todd S, Miller D, Valdés-Márquez E, Stallard N, Friede T (2011) A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis 17: 81-88.

2010
• Nicholas R, Young C, Friede T (2010) Bladder symptoms in Multiple Sclerosis: a review of pathophysiology and management. Expert Opinion on Drug Safety: 905-915.
• Stallard N, Friede T (2010) Efficiency of adaptive designs. In: Chow, Pong (eds.) Handbook of adaptive designs in pharmaceutical and clinical development, Taylor & Francis, Chapter 25 (pages 25-1 to 25-16).
• Benda N, Brannath W, Bretz F, Burger HU, Friede T, Maurer W, Wang SJ (2010) Perspectives on the use of adaptive designs in clinical trials: Part II Panel Discussions. Journal of Biopharmaceutical Statistics 20: 1098 – 1112.
• Friede T, Schmidli H (2010) Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods of Information in Medicine 49:618-624.
• Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdés-Márquez E, Chataway J (2010) Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis. Drug Information Journal 44: 713-718.
• Friede T, Stammer H (2010) Blinded sample size recalculation in non-inferiority trials: A case study in dermatology. Drug Information Journal 44: 599-607.
• Benda N, Branson M, Maurer W, Friede T (2010) Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44: 299-315.
• Friede T, Schmidli H (2010) Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicine 29: 1145-1156.
• Holt TA, Thorogood M, Griffiths F, Munday S, Friede T, Stables D (2010) Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial [ISRCTN64828380]. British Journal of General Practice 60:251-256.

2009
• Benda N, Branson M, Maurer W, Friede T (2009) Clinical Scenario Evaluation: A framework for the evaluation of competing development strategies. Drug Development 4: 84-88.
• Dale J, Caramlau I, Sturt J, Friede T, Walker R (2009) Telephone Peer-delivered Intervention for Diabetes Education and Support: The Telecare Exploratory RCT. Patient Education and Counseling 75: 91–98.
• Nicholas RS, Friede T, Hollis S, Young CA (2009) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.
• Miller F, Friede T, Kieser M (2009) Blinded assessment of treatment effects utilising information about the randomisation block length. Statistics in Medicine 28: 1690–1706. DOI: 10.1002/sim.3576
• Stallard N, Posch M, Friede T, Koenig F, Brannath W (2009) Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine 28: 1321–1338.
• Friede T, Henderson R (2009) Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 8: 62-72.

2008
• Robertson W, Friede T, Blissett J, Rudolf MCJ, Wallis M, Stewart-Brown S (2008) Pilot of the Families for Health programme for the treatment of obesity. Archives of Disease in Childhood 93: 921–926.
• Friede T, Dunn J, Stallard N (2008) Clinical trials in oncology. In: Missailidis S (ed.): Anticancer therapeutics, Wiley-Blackwell, Chichester. Pages 365-375.
• Friede T, Stallard N (2008) A comparison of methods for adaptive treatment selection. Biometrical Journal 50: 767-781.
• Stallard N, Friede T (2008) Flexible group-sequential designs for clinical trials with treatment selection. Statistics in Medicine 27: 6209-6227.

2007
• Rog DJ, Nurmikko TJ, Friede T, Young CA (2007) Validation and reliability of the neuropathic pain scale (NPS) in multiple sclerosis. Clinical Journal of Pain 23: 473–481.
• Friede T, Mitchell C, Müller-Velten G (2007) Blinded sample size reestimation in non-inferiority studies with binary endpoints. Biometrical Journal 49: 903-916.
• Kieser M, Friede T (2007) Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in Medicine 26: 253-273.
• Friede T, Henderson R, Kao CF (2006) A note on testing for intervention effects on binary responses. Methods of Information in Medicine 45: 435-440.


---

  Zurück   Seitenanfang